Advertisement

Antibodies pp 183-187 | Cite as

Antitumor Antibodies: From Research to Clinic

  • Sylvie Ménard
  • Serenella M. Pupa
  • Manuela Campiglio
  • Elda Tagliabue

Abstract

Over the last 15 years, we have produced monoclonal antibodies directed specifically against tumor cells, especially carcinoma cells. 150.000 supernatants of growing hybridoma cells coming from 150 different somatic fusions of spleen cells from mice immunized with different immunogens and protocols, were screened for specific reactivity on tumor cells. Only 45 monoclonal antibodies were selected for basic researches and clinical applications.

Keywords

Somatic Fusion Bispecific Monoclonal Antibody Antitumor Antibody Bivalent Antibody Sacchini Versus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balsari AL, Morelli D, Ménard S, Veronesi U. Colnaghi MI. 1994. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 8:226–230.PubMedGoogle Scholar
  2. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksai H, Mendelsohn J. 2000. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904–914.PubMedGoogle Scholar
  3. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH. 1995. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463–1469.PubMedCrossRefGoogle Scholar
  4. Herbst RS, Langer CJ. 2002. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27–36.PubMedCrossRefGoogle Scholar
  5. Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI. 1999. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 55:169–177.PubMedCrossRefGoogle Scholar
  6. Ménard S, Squicciarini P, Luini A, Sacchini V, Rovini D, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi MI. 1994. Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumor prognostic features. Br J Cancer 69:1126–1129.PubMedCrossRefGoogle Scholar
  7. Morelli D, Villa E, Tagliabue E, Perletti L, Villa ML, Ménard S, Balsari A, Colnaghi MI. 1994. Relevance of antibody valency in EGF receptor modulation. Scand J Immunol 39:453–458.PubMedCrossRefGoogle Scholar
  8. Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donate NJ. 1992. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: Evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res 52:4758–4765.PubMedGoogle Scholar
  9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paten V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792.PubMedCrossRefGoogle Scholar
  10. Tagliabue E, Porro G, Barbanti P, Delia Torre G, Ménard S, Rilke F, Colnaghi MI. 1986. Improvement of tumor cell detection using a pool of monoclonal antibodies. Hybridoma 5:107–115.PubMedCrossRefGoogle Scholar
  11. van Zanten-Przybysz I, Molthoff CF, Roos JC, Verheijen RH, van Hof A, Buist MR, Prinssen HM, Den Hollander W, Kenemans P. 2001. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer 92:106–114.PubMedGoogle Scholar
  12. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Sylvie Ménard
    • 1
  • Serenella M. Pupa
    • 1
  • Manuela Campiglio
    • 1
  • Elda Tagliabue
    • 1
  1. 1.Molecular Targeting Unit, Dept. of Experimental OncologyIstituto Nazionale TumoriMilanItaly

Personalised recommendations